RPID

Rapid Micro is a sub-scale ($33.6M revenue) life-sciences instrument maker whose Growth Direct automated microbial-QC platform is finally showing commercial traction: revenue grew 19.7% in FY2025 and has climbed every year since the FY2022 trough ($17.1M → $22.5M → $28.1M → $33.6M). The February 2025 Distribution and Collaboration Agreement with MilliporeSigma (Merck KGaA's Life Science arm) is the most important development in the filing — a five-year, global co-exclusive sales channel with a minimum Growth Direct purchase commitment over the first two years, plus a contemplated supply agreement explicitly aimed at 'accelerating gross margin.' That validation and built-in demand are why this is not an outright avoid.

But the income statement remains brutal. FY2025 produced a -$47.1M net loss (operating margin -141%, net margin -140%, ROE -142%), essentially flat with FY2024 despite the revenue gains — the loss is not narrowing alongside growth. The accumulated deficit is $522M against just $33.2M of stockholders' equity, which itself fell 55.9% year-over-year, while total liabilities jumped 82.5% and long-term debt sits at $18.9M. This is a company that has consumed half a billion dollars and still cannot self-fund.